Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2

Cancer Research

Volumn 62, Issue 19, 2002, Pages 5463-5469

  Zhang, Lei ^a   Gasper, Warren J ^a   Stass, Sanford A ^a   Ioffe, Olga B ^a   Davis, Myrtle A ^a   Mixson, A James ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; DNAZYME; KI 67 ANTIGEN; LIPOSOME; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL; CANCER INHIBITION; CATTLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BASE SEQUENCE; CATTLE; CELL DIVISION; DNA, CATALYTIC; ENDOTHELIUM, VASCULAR; HUMANS; KI-67 ANTIGEN; MICE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 0036792125     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Santoro, S. W., and Joyce, G. F. A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. USA. 94: 4262-4266, 1997.
2. Finkel, E. DNA cuts its teeth-as an enzyme. Science (Wash. DC). 286: 2441-2442, 1999.
3. Sioud, M., and Leirdal, M. Design of nuclease resistant protein kinase Cα DNA enzymes with potential therapeutic application. J. Mol. Biol., 296: 937-947, 2000.
4. Crooke, S. T., and Bennett, C. F. Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol., 36: 107-129, 1996.
5. Dean, N. M., and Griffey, R. H. Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev., 7: 229-233, 1997.
6. Dryden, S., Pickavance, L., Tidd, D., and Williams, G. The lack of specificity of neuropeptide Y (NPY) antisense oligodeoxynucleotides administered intracerebro-ventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus. J. Endocrinol., 157: 169-175, 1998.
7. Goodchild, J. Hammerhead ribozymes: biochemical and chemical considerations. Curr. Opin. Mol. Ther., 2: 272-281, 2000.
8. Shimayama, T., Nishikawa, S., and Taira, K. Generality of the NUX rule: kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes. Biochemistry, 34: 3649-3654, 1995.
9. Kuwabara. T., Warashina, M., Tanabe, T., Tani, K., Asano, S., and Taira, K. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Nucleic Acids Res., 25: 3074-3081, 1997.
10. Folkman, J. Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. USA. 95: 9064-9066, 1998.
11. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
12. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (Lond.), 367: 576-579, 1994.
13. Sandberg, J. A., Bouhana, K. S., Gallegos, A. M., Agrawal, A. B., Grimm, S. L., Wincott, F. E., Reynolds, M. A., Pavco, P. A., and Parry, T. J. Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse. Antisense Nucleic Acid Drug Dev., 9: 271-277, 1999.
14. Weng, D. E., and Usman, N. Angiozyme: a novel angiogenesis inhibitor. Curr. Oncol. Rep., 3: 141-146. 2001.
15. Wu, Y., Yu, L., McMahon, R., Rossi, J. J., Forman, S. J., and Snyder, D. S. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum. Gene Ther., 10: 2847-2857, 1999.
16. Sriram, B., and Banerjea, A. C. In vitro-selected RNA cleaving DNA enzymes from a combinatorial library are potent inhibitors of HIV-1 gene expression. Biochem. J., 352 Pt 3: 667-673. 2000.
17. Unwalla, H., and Banerjea, A. C. Inhibition of HIV-I gene expression by novel macrophage-tropic DNA enzymes targeted to cleave HIV-I TAT/Rev RNA. Biochem. J., 357: 147-155, 2001.
18. Santiago, F. S., Lowe, H. C., Kavurma, M. M., Chesterman, C. N., Baker, A., Atkins, D. G., and Khachigian, L. M. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat. Med., 5: 1264-1269, 1999.
19. Chen, Q. R., Zhang, L., Stass, S. A., and Mixson, A. J. Branched co-polymers of histidine and lysine are efficient carriers of plasmids. Nucleic Acids Res., 29: 1334-1340, 2001.
20. Chen, Q. R., Zhang, L., Stass, S. A., and Mixson, A. J. Co-polymer of histidine and lysine markedly enhances transfection of liposomes. Gene Ther., 7: 698-704, 2000.
21. Kimura, M., Amemiya, K., Yamada, T., and Suzuki, J. Quantitative method for measuring adjuvant-induced granuloma angiogenesis in insulin-treated diabetic mice. J. Pharmacobio-Dyn., 9: 442-446, 1986.
22. Cruz, D., Valenti, C., Dias, A., Seixas, M., and Schmitt, F. Microvessel density counting in breast cancer. Slides vs. digital images. Am. J. Epidemiol., 23: 15-20, 2001.
23. Gasparini, G., Weidner, N., Maluta, S., Pozza, F., Boracchi. P., Mezzetti, M., Testolin, A., and Bevilacqua, P. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int. J. Cancer, 55: 739-744, 1993.
24. Gasparini, G., Brooks, P. C., Biganzoli. E., Vermeulen, P. B., Bonoldi, E., Dirix, L. Y., Ranieri, G., Miceli, R., and Cheresh, D. A. Vascular integrin α(v)β3: a new prognostic indicator in breast cancer. Clin. Cancer Res., 4: 2625-2634, 1998.
25. Mentzel, T., Brown, L. F., Dvorak, H. F., Kuhnen, C., Stiller, K. J., Katenkamp, D., and Fletcher, C. D. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Arch., 438: 13-22, 2001.
26. Cairns, M. J., Hopkins, T. M., Withenngton, C., Wang, L., and Sun, L. Q. Target site selection for an RNA-cleaving catalytic DNA. Nat. Biotechnol., 17: 480-486, 1999.
27. de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (Wash. DC), 255: 989-991, 1992.
28. Machein, M. R., Risau, W., and Plate, K. H. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum. Gene Ther., 10: 1117-1128, 1999.
29. Breaker, R. R., and Joyce, G. F. A DNA enzyme with Mg(2+)-dependent RNA phosphoesterase activity. Chem. Biol., 2: 655-660, 1995.
30. Breaker, R. R., and Joyce, G. F. A DNA enzyme that cleaves RNA. Chem. Biol., 1: 223-229, 1994.
31. Geyer, C. R., and Sen, D. Evidence for the metal-cofactor independence of an RNA phosphodiester-cleaving DNA enzyme. Chem. Biol., 4: 579-593, 1997.
32. Sun, L. Q., Cairns, M. J., Gerlach, W. L., Witherington, C., Wang, L., and King, A. Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme. J. Biol. Chem., 274: 17236-17241, 1999.
33. Cuenoud, B., and Szostak, J. W. A DNA metalloenzyme with DNA ligase activity. Nature (Lond.), 375: 611-614, 1995.
34. Li, Y., and Breaker, R. R. Phosphorylating DNA with DNA. Proc. Natl. Acad. Sci. USA. 96: 2746-2751, 1999.
35. Li, Y., and Sen, D. A catalytic DNA for porphyrin metallation. Nat. Struct. Biol., 3: 743-747, 1996.
36. Sato, Y., Roman, M., Tighe, H., Lee, D., Corr, M., Nguyen, M. D., Silverman, G. J., Lotz, M., Carson, D. A., and Raz. E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (Wash. DC), 273: 352-354, 1996.
37. Wloch, M. K., Pasquini, S., Ertl, H. C., and Pisetsky, D. S. The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors. Hum. Gene Ther., 9: 1439-1447, 1998.
38. Dow, S. W., Fradkin, L. G., Liggitt, D. H., Willson. A. P., Heath, T. D., and Potter, T. A. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol., 163: 1552-1561, 1999.
39. Pisetsky, D. S. The influence of base sequence on the immunostimulatory properties of DNA. Immunol. Res., 19: 35-46, 1999.
40. Garcia-Chaumont, C., Seksek, O., Grzybowska, J., Borowski, E., and Bolard, J. Delivery systems for antisense oligonucleotides. Pharmacol. Ther., 87: 255-277, 2000.
41. Ponnappa, B. C., and Israel, Y. Targeting Kupffer cells with antisense oligonucleotides. Front. Biosci., 7: e223-e233. 2002.
42. Xu, M., Kumar D., Srinivas S., DeTolla, L. J., Yu, S. F., Stass, S. A., and Mixson, A. J. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum. Gene Ther., 8: 177-185, 1996.
43. Juliano, R. L., and Akhtar, S. Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res. Dev., 2: 165-176, 1992.
44. Clark, R. E. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia. Leuk. Lymphoma, 19: 189-195, 1995.
45. Hu, Q., Shew, C. R., Bally, M. B., and Madden, T. D. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects. Biochim. Biophys. Acta, 1514: 1-13, 2001.
46. Chen, Q. R., Zhang, L., Luther, P. W., and Mixson, A. J. Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles. Nucleic Acids Res., 30: 1338-1345, 2002.